ArticleDiscover oncology2026
Outcomes of primary gastrointestinal diffuse large B cell lymphoma in the rituximab era.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPrimary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) constitutes 30%-40% of primary extranodal lymphomas. While rituximab has significantly improved survival in nodal DLBCL, its impact on the prognosis of PGI-DLBCL remains inadequately defined. This study aimed to compare the survival outcomes of PGI-DLBCL patients between the pre-rituximab and rituximab eras.
methodsWe identified all PGI-DLBCL cases from the Surveillance, Epidemiology, and End Results (SEER) registry (1975-2015). Patients were categorized into pre-rituximab (diagnosed before 2006) and rituximab-era (diagnosed in or after 2006) groups. Overall survival (OS) and lymphoma-specific survival (LSS) were compared between the two groups.
resultsAmong 2780 patients, median age was 68 years; 72.2% had stage I/II disease. The rituximab-era group showed significantly longer median OS (119 months vs. 43 months, p < 0.0001). Median LSS was not reached in the rituximab era versus 115 months in the pre-rituximab group (p < 0.0001), with an 11-year LSS rate of 58%. Multivariable analysis confirmed that the rituximab era, younger age, early stage, and chemotherapy were associated with better OS and LSS.
conclusionsPGI-DLBCL represents a significant subset of non-Hodgkin lymphomas and is the most prevalent type within the gastrointestinal tract. Younger age, female, Asian, marital status, early-stage and with chemotherapy, as well as the period of lymphoma diagnosis (rituximab era), are associated with better prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.